logo
Select company
Select metric
$ -134.34MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
6
Sector
13
Industry
20
History
3
$ 16.95Close
$ 3.93 - $ 21.42 52-Week Range
Ticker Information

Ticker

URGN

Company Name

UROGEN PHARMA LTD

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

UROGEN PHARMA LTD - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

URGN - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 1.67M$ -136.01M$ -134.34M
3/31/2025$ 1.33M$ -121.12M$ -119.79M
12/31/2024$ 1.19M$ -111.52M$ -110.33M
9/30/2024$ 1.3M$ -99.13M$ -97.82M
6/30/2024$ 1.45M$ -96.34M$ -94.89M
3/31/2024$ 1.62M$ -86.75M$ -85.13M
12/31/2023$ 1.71M$ -83.61M$ -81.9M
9/30/2023$ 1.73M$ -89.99M$ -88.26M
6/30/2023$ 1.75M$ -94.34M$ -92.59M
3/31/2023$ 1.8M$ -98.44M$ -96.65M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • UROGEN PHARMA LTD's latest trailing twelve months (TTM) EBITDA stands at $ -138.7M.
  • Over the past 5 years, UROGEN PHARMA LTD's average EBITDA has been $ -105.53M.
  • The median EBITDA for UROGEN PHARMA LTD during this period was $ -106.55M
  • UROGEN PHARMA LTD reached its highest EBITDA over the past 5 years at $ -81.9M.
  • The lowest EBITDA recorded by UROGEN PHARMA LTD in the same timeframe $ -138.7M

UROGEN PHARMA LTD's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
NRIX : NURIX THERAPEUTICS INC $ -225.49MSNDX : SYNDAX PHARMACEUTICALS INC $ -313.35MGYRE : GYRE THERAPEUTICS INC $ 9.86MCRMD : CORMEDIX INC $ 52.25MNAGE : NIAGEN BIOSCIENCE INC $ 19.78MZYME : ZYMEWORKS INC $ -54.55MPHAT : PHATHOM PHARMACEUTICALS INC $ -256.75MTBPH : THERAVANCE BIOPHARMA INC $ 48.42MWVE : WAVE LIFE SCIENCES LTD $ -121.2MKURA : KURA ONCOLOGY INC $ -192.46M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for UROGEN PHARMA LTD is calculated as follows: EBIT [ $ -141.26M ] + DepAmor [ $ 2.56M ]
(=) EBITDA [ $ -138.7M ]

URGN - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -138.7M

Minimum

Sep 30, 2020

$ -81.9M

Maximum

Dec 31, 2023

$ -105.53M

Average

$ -106.55M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M